Padcev (enfortumab vedotin-ejfv) - Astellas, Pfizer
petosemtamab (MCLA-158) - Genmab
ficerafusp alfa (BCA101) - Bicara Therapeutics
Erbitux (cetuximab) - Eli Lilly
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Tafinlar (dabrafenib) - Novartis
izalontamab brengitecan (BL-B01D1) - Biokin Pharma, BMS
Cotelet (tagitanlimab) - Harbour BioMed
Meiyouheng (becotatug vedotin) - Lepu Med
Bavencio (avelumab) - EMD Serono
Keytruda (pembrolizumab) - Merck (MSD)
izalontamab (SI-B001) - Biokin Pharma
becotarug (JMT101) - CSPC Pharma
AiRuiKa (camrelizumab) - Elevar Therapeutics
Loqtorzi (toripalimab-tpzi) - Shanghai Junshi Biosci, Coherus Oncology
Mekinist (trametinib) - Novartis, BeOne Medicines
http://www.ncbi.nlm.nih.gov/pubmed/41789685
 
Joanna A Vuille; Petr Szturz
 
Mar 6, 2026
 
Prev Next